

Biomarker-guided management of NSCLC: Current and future strategies



Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities*
- *touchIME accepts no responsibility for errors or omissions*

Clinical case – Jenny

Patient history

- Female
- 71 years old
- Never-smoker
- Persistent cough
- Haemoptysis
- Dyspnoea
- Fatigue
- Weight loss
- Loss of appetite
- Oedema



Diagnosis

- **Chest x-ray:** left pleural effusion
- **CT scan:** tumour with 4 cm diameter in the left lower lobe and 3 cm nodule considered to be a metastasis in the liver
- **PET scan:** multiple hypermetabolic masses in the left lung and lymph nodes, hypermetabolic activity in the right supraclavicular region
- **MRI:** no brain metastases
- **Percutaneous thoracocentesis:** pleural effusion drainage and cell pellet
- **Stage IV NSCLC (adenocarcinoma)**
- **ECOG-PS at diagnosis: 2**

Biomarker-guided treatment

IHC results

- PD-L1 expression of 60%

NGS panel results

- *MET* exon 14 skipping mutation
- *TP53* mutation
- Low TMB
- MSS

Treatment*

- **Capmatinib** (FDA and MHLW approved)^{1,2}
- **Tepotinib** (FDA and MHLW approved)^{3,4}
- **Crizotinib** (FDA breakthrough designation)⁵
- *Other treatments are under investigation*

* ESMO recommended for patients with NSCLC harbouring *MET* exon 14 mutations [LoE: III; GoR: B]⁶

CT, computerized tomography; ECOG-PS, Eastern Cooperative Oncology Group performance status; ESMO, European Society of Medical Oncology; FDA, US Food and Drug Administration; GoR, grade of recommendation; IHC, immunohistochemistry; LoE, level of evidence; *MET*, mesenchymal-epithelial transition factor proto-oncogene; MHLW, Japanese Ministry of Health, Labour and Welfare; MRI, magnetic resonance imaging; MSS, microsatellite stable; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; PET, positron emission tomography; PI, prescribing information; TMB, tumour mutational burden; *TP53*, tumour protein 53. 1. FDA. [Capmatinib tablets, PI](#). 2020; 2. Novartis. [Press release, Capmatinib](#). 29 June 2020; 3. FDA. [Tepotinib tablets, PI](#). 2021; 4. Merck KGaA. [Press release, Tepotinib](#). 25 March 2020; 5. Pfizer. [Press release, Crizotinib](#). 29 May 2018; 6. Planchard D, et al. [Ann Oncol](#). 2018;29(Suppl. 4):iv192–237. Updated September 2020. (all accessed 23 June 2021).